New synthetic drugs lure self-treating users with dangerous, unpredictable effects

People who feel shut out of effective addiction care are increasingly taking matters into their own hands, and the drugs they are choosing can be far more dangerous than they expect. The National Institute on Drug Abuse says emerging drugs have unpredictable health effects, may be as powerful as existing drugs or stronger, and may be fatal.

The risk is not confined to a narrow corner of the market. NIDA says these substances are sold in drug markets, convenience stores and online, where people may use them to self-medicate without medical supervision and without knowing what they actually took. Since 2013, the United Nations Office on Drugs and Crime has identified more than 1,000 emerging drugs worldwide, a pace that has outstripped the capacity of public health systems to track them.

Among the most visible are synthetic cannabinoids such as K2 and Spice, which the Drug Enforcement Administration says are marketed under the guise of “herbal incense” or “potpourri.” The drugs carry dozens of street names and are packaged without information about health or safety risks. They are also harder to detect with conventional urine drug tests, which can leave clinicians and families with little warning about what is driving a crisis.

A 2025 systematic review in European Addiction Research found only 11 eligible case reports of synthetic cannabinoid withdrawal, but the symptoms documented were severe. Psychosis, agitation, nausea and vomiting, seizures, tachycardia and insomnia were among the most common. In some cases, patients developed delirium, rhabdomyolysis and hallucinations. Symptoms often began within 24 to 48 hours and sometimes required prompt medical management.

The problem is being intensified by the speed of illicit production. A 2026 Partnership to End Addiction report said underground labs are creating new synthetic drugs so quickly that compounds can reach the market long before health agencies know they exist, making regulation difficult and leaving potency and effects unknown. Public-health and forensic groups have warned that this moving target is increasingly visible in emergency rooms, death investigations and corrections settings, where synthetic cannabinoids continue to pose a significant challenge.

That warning lands in a country that still faces a major overdose crisis. Centers for Disease Control and Prevention provisional data estimated 80,391 drug overdose deaths in the United States in 2024, a 26.9 percent drop from 2023. Even with that decline, the appearance of new synthetic compounds shows how quickly the landscape can change when treatment feels out of reach and desperate users begin experimenting on themselves.